MIRAPEX ER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MIRAPEX ER (MIRAPEX ER).
Non-ergot dopamine agonist with high affinity for D2 and D3 receptor subtypes; stimulates dopamine receptors in the striatum.
| Metabolism | Primarily hepatic via CYP1A2; also N-dealkylation and glucuronidation; <10% excreted unchanged in urine. |
| Excretion | Renal excretion of unchanged drug and metabolites: ~90% in urine (pramipexole: ~70% unchanged; N-desmethyl metabolite: ~20%). Fecal excretion: ~2%. Biliary elimination: minimal. |
| Half-life | Terminal elimination half-life: 8–12 hours in young healthy adults; prolonged to 16–40 hours in elderly (≥65 years) and up to 30 hours in moderate renal impairment (CrCl 20–50 mL/min). |
| Protein binding | 15% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | 500 L (≈7 L/kg), indicating extensive tissue distribution. |
| Bioavailability | Oral extended-release: 90% (relative to immediate-release); absolute bioavailability >90%. |
| Onset of Action | Extended-release oral: 1–2 weeks to achieve steady-state therapeutic effect; initial clinical response may be observed within 1 week. |
| Duration of Action | 24 hours (once-daily dosing) due to extended-release formulation; clinical effects maintained over 24-hour dosing interval. |
Oral, start 0.375 mg once daily, titrate weekly by 0.375 mg/dose to 1.5 mg once daily (immediate-release); ER: same total daily dose once daily.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | CrCl 30-50 mL/min: start 0.375 mg once daily, max 1.5 mg/day. CrCl 15-29 mL/min: start 0.375 mg every other day. CrCl <15 mL/min or hemodialysis: not recommended. |
| Liver impairment | No specific adjustment recommended for hepatic impairment; use with caution. |
| Pediatric use | Not established; safety and efficacy in pediatric patients have not been determined. |
| Geriatric use | No specific dosage adjustment required; monitor for hallucinations, postural hypotension, and somnolence. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MIRAPEX ER (MIRAPEX ER).
| Breastfeeding | It is not known whether pramipexole is excreted in human milk; M/P ratio is not available. In animal studies, pramipexole was excreted in rat milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants (e.g., somnolence, dyskinesia), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. |
| Teratogenic Risk | Pregnancy Category C. Pramipexole has been shown to be teratogenic in animal studies (postimplantation loss and decreased fetal weight) at doses similar to human therapeutic doses. There are no adequate and well-controlled studies in pregnant women. Risk cannot be ruled out. For first trimester: potential risk based on animal data. Second and third trimesters: unknown risk; however, the drug should only be used if potential benefit justifies potential risk. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
["Hypersensitivity to pramipexole or any component of the formulation"]
| Precautions | ["May cause somnolence and sudden sleep onset during daily activities","Risk of hypotension, especially orthostatic","May cause impulse control disorders (e.g., pathological gambling, hypersexuality)","May cause hallucinations and psychotic-like behavior","Risk of dyskinesia or exacerbation of pre-existing dyskinesia","Risk of fibrotic complications (e.g., pleural effusion, retroperitoneal fibrosis) with chronic use","Caution in patients with severe cardiovascular disease"] |
Loading safety data…
| Fetal Monitoring | Monitor for maternal adverse effects including orthostatic hypotension, hallucinations, somnolence, and impulse control disorders. For fetus: no specific monitoring recommendations; however, consider fetal monitoring if maternal complications arise (e.g., severe hypotension). Clinical monitoring of fetal growth and well-being per standard obstetric care is advised. |
| Fertility Effects | In animal studies, pramipexole caused prolonged estrous cycles and reduced implantation rates at doses similar to human therapeutic doses. In males, no adverse effects on fertility were observed. The clinical significance in humans is unknown; however, potential for transient impairment of fertility in females. |